Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

2024-07-08T02:39:06Z

Created page with "Category: Drugs Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."

New page

[[Category: Drugs]][[Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

[[:Category: Antidiabetic Drug | '''Antidiabetic Drug''']]

'''Drug class: [[:Category: Sodium-glucose co-transporter 2 (SGLT2) inhibitor | Sodium-glucose co-transporter 2 (SGLT2) inhibitor]]

'''Empagliflozin (JARDIANCE)'''（中文：[[恩格列淨]]）
==Common Strengths of Empagliflozin Tablet==
Empagliflozin tablets are available in the following strengths:
*10 mg and 25 mg tablets

==Drug Trade Names of Empagliflozin Tablet==
Jardiance

==Drug Usage==
*Treatment of type 2 diabetes mellitus
*Reducing the risk of major adverse cardiovascular events (including myocardial infarction, stroke or death) in adults with type 2 diabetes or who are at risk for cardiovascular disease.
*Reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease

==Mechanism of Action==
Inhibits sodium-glucose co-transporter-2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion

==Route of Administration==
Oral

==Dosages==
*Type 2 diabetes: 10 mg once daily, can be increased to 25 mg once daily
*Heart failure: 10 mg once daily
*Chronic kidney disease: 10 mg once daily
Renal dose based on eGFR:
*eGFR ≥ 45 mL/min/1.73 m2: No dose adjustment required
*eGFR 30 to < 45 mL/min/1.73 m2: Use is not recommended for glycemic control
*eGFR < 30 mL/min/1.73 m2: Use is contraindicated

==Side Effects==
{| class="wikitable"
!style="text-align: left"| Frequency
!Adverse reactions
|-
| rowspan="3" | '''Common
| Urinary tract infection
|-
| Vaginal yeast infection
|-
| Increased urination
|-
| rowspan="4" | '''Uncommon
| Diabetic ketoacidosis (DKA) - a condition where blood becomes too acidic
|-
| Hypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas
|-
| Hypotension
|-
| Fournier's gangrene
|}

==Pharmacokinetics==
*Absorption
**Rapidly absorbed with peak plasma concentrations at 1.5 hours post-dose
*Metabolism
**Primarily through glucuronidation
*Elimination
**Half-life is approximately 12.4 hours
*Duration of action
**24 hours after once-daily dosing

==Drug Precautions==
'''Pregnancy

Not recommended during pregnancy

'''Breastfeeding

Not recommended during breastfeeding

'''Children and Elderly

Not recommended for children under 10 years. No dose adjustment is required for elderly patients

'''Renal impairment

Use with caution in patients with renal impairment

'''Monitoring Requirements

Renal function, signs of ketoacidosis, genital mycotic infections, volume status

'''Drug Interaction

May increase the risk of hypoglycemia when used with insulin or insulin secretagogues

==FAQ==
'''How Should I Take the Tablet?

Take once daily in the morning, with or without food

'''What Should I Avoid While Taking?

Avoid excessive alcohol consumption and dehydration

'''What Happens if I Miss a Dose?

Take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose

Empagliflozin - Revision history

Zeki: Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..."